Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CCR
    (2)
  • VEGFR
    (2)
  • FAK
    (1)
  • Integrin
    (1)
  • Liposome
    (1)
  • Serine/threonin kinase
    (1)
  • Src
    (1)
  • Others
    (2)
Filter
Search Result
Results for "

neovascular

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
SPHINX31
T51941818389-84-2
SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50: 5.9 nM).
  • $34
In Stock
Size
QTY
JP-153
T2064421802937-26-3
JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.
  • Inquiry Price
10-14 weeks
Size
QTY
ALK4290
ALK4290
T366201251528-23-0
ALK4290 (AKST4290) is a potent, orally active CCR3 inhibitor (compound Example 2) with a Ki of 3.2 nM for hCCR3[1], suitable for research into neovascular age-related macular degeneration and Parkinsonism[2][3].
  • $1,520
6-8 weeks
Size
QTY
AG-13958 monohydrochloride
T69452319463-49-5
AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF.
  • $1,520
6-8 weeks
Size
QTY
Brolucizumab
RTH258, ESBA 1008, DLX1008
T805931531589-13-5
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
  • $813
In Stock
Size
QTY
Cyclo(RGDyC)
T826411206475-79-7
Cyclo(RGDyC), a cyclic pentapeptide, exhibits anti-angiogenic properties and has been investigated in conjunction with liposomal delivery systems for the study of ocular neovascular diseases and cancer [1] [2].
  • Inquiry Price
Size
QTY
ALK4290 dihydrochloride
AKST4290 dihydrochloride
T856261372127-19-9
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) serves as a potent and orally active inhibitor of CCR3, exhibiting a K i of 3.2 nM for hCCR3 [1]. It is primarily used in research related to neovascular age-related macular degeneration and Parkinsonism [2] [3].
  • $1,650
6-8 weeks
Size
QTY
DSPE-PEG2000-cRGD
TCL-01138
DSPE-PEG2000-cRGD is a PEG compound composed of DSPE and an αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. This compound can be utilized for drug delivery.
  • Inquiry Price
Size
QTY